On December 22, 2015 Stemline Therapeutics, Inc. (Nasdaq:STML) reported the opening of its SL-801 Investigational New Drug (IND) application and initiation of a broad clinical development program in multiple cancer types (Press release, Stemline Therapeutics, DEC 22, 2015, View Source [SID:1234508628]). SL-801 is an oral, reversible, small molecule inhibitor of Exportin 1 (XPO1), a promising and clinically validated oncology target overexpressed by many solid and hematologic cancers. SL-801 has demonstrated robust anti-cancer activity in animal models of multiple solid and hematologic malignancies.

Ivan Bergstein, M.D., Stemline’s Chief Executive Officer, stated, "We are pleased to have successfully advanced the SL-801 program quickly through IND opening. Our SL-801 development strategy builds upon current knowledge in the XPO1 space and is designed to evaluate the agent’s clinical potential across multiple cancer types early in the program." Dr. Bergstein concluded, "The clinical debut of SL-801 serves to advance our pipeline and greatly strengthen the company’s clinical and commercial potential."